Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is scheduled to issue its quarterly earnings data before the market opens on Wednesday, October 25th. Analysts expect the company to announce earnings of $1.33 per share for the quarter. Alexion Pharmaceuticals has set its FY17 guidance at $5.40-5.55 EPS.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.08 by $0.48. The business had revenue of $912.00 million during the quarter, compared to the consensus estimate of $846.15 million. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The business’s revenue was up 21.1% compared to the same quarter last year. During the same quarter last year, the firm posted $1.13 EPS. On average, analysts expect Alexion Pharmaceuticals to post $5.60 EPS for the current fiscal year and $7.13 EPS for the next fiscal year.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at 143.16 on Wednesday. Alexion Pharmaceuticals, Inc. has a one year low of $96.18 and a one year high of $149.34. The stock has a 50 day moving average of $142.24 and a 200-day moving average of $127.19. The stock has a market cap of $31.95 billion, a P/E ratio of 62.08 and a beta of 1.39.
COPYRIGHT VIOLATION WARNING: This news story was first published by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/2966936/alexion-pharmaceuticals-inc-alxn-set-to-announce-quarterly-earnings-on-wednesday.html.
A number of equities research analysts recently weighed in on the stock. TheStreet upgraded shares of Alexion Pharmaceuticals from a “c” rating to a “b-” rating in a research note on Friday, July 14th. SunTrust Banks, Inc. restated a “buy” rating and set a $165.00 price objective on shares of Alexion Pharmaceuticals in a research note on Friday, July 14th. UBS AG restated a “buy” rating and set a $142.00 price objective (up from $140.00) on shares of Alexion Pharmaceuticals in a research note on Monday, June 26th. BidaskClub upgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, July 25th. Finally, Deutsche Bank AG restated a “buy” rating and set a $158.00 price objective (up from $153.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. Six research analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $154.56.
In related news, Director Ann M. Veneman sold 700 shares of Alexion Pharmaceuticals stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $137.74, for a total value of $96,418.00. Following the transaction, the director now owns 6,315 shares of the company’s stock, valued at approximately $869,828.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Julie O’neill sold 11,160 shares of Alexion Pharmaceuticals stock in a transaction dated Monday, August 28th. The stock was sold at an average price of $140.00, for a total value of $1,562,400.00. Following the completion of the transaction, the executive vice president now directly owns 26,704 shares in the company, valued at approximately $3,738,560. The disclosure for this sale can be found here. Insiders sold a total of 17,190 shares of company stock worth $2,433,669 in the last three months. 4.35% of the stock is currently owned by company insiders.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.